نتایج جستجو برای: mph
تعداد نتایج: 3367 فیلتر نتایج به سال:
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental commencing before the age of 12 years and characterized by developmentally inappropriate inattention, hyperactivity, and/or impulsivity symptoms. Stimulants such as methylphenidate (MPH) are used first-line therapy for children with ADHD. Psychostimulants may be associated vascular problems. Raynaud’s phenomenon (RP) periph...
Carrie D. Patnode, PhD, MPH; Jillian T. Henderson, Erin L. Coppola, Joy Melnikow, MD, Shauna Durbin, Rachel G. Thomas, MPH
Cynthia Feltner, MD, MPH; Ina F. Wallace, PhD; Christine E. Kistler, MASc; Manny Coker-Schwimmer, Daniel Jonas, MPH
BACKGROUND The main aim of this study was to compare the safety and efficacy of IR MPH administered three times daily to those of once daily OROS-MPH. METHODS Subjects were outpatient adults satisfying full diagnostic criteria for DSM-IV ADHD between 19 and 60 years of age. Data from two independently conducted 6-week placebo controlled, randomized clinical trials of IR-MPH (tid) and of OROS-...
dl-Methylphenidate (MPH) has been widely used to treat attention-deficit/hyperactivity disorder (ADHD) for the last half century. It had been exclusively available in the racemic form, i.e., a 50:50 mixture of d- and l-isomers. However, a single enantiomer formulation, d-MPH (dexmethylphenidate), became available for general clinical use in 2002. For this reason, the intrinsic pharmacological d...
Dariush Mozaffarian, MD, DrPH, FAHA; Emelia J. Benjamin, MD, ScM, FAHA; Alan S. Go, MD; Donna K. Arnett, PhD, MSPH, FAHA; Michael J. Blaha, MD, MPH; Mary Cushman, MD, MSc, FAHA; Sandeep R. Das, MD, MPH; Sarah de Ferranti, MD, MPH; Jean-Pierre Després, PhD, FAHA; Heather J. Fullerton, MD, MAS; Virginia J. Howard, PhD, FAHA; Mark D. Huffman, MD, MPH, FAHA; Carmen R. Isasi, MD, PhD; Monik C. Jimén...
Associate Editors Derek C. Angus, MD, MPH, Ethan Basch, MD, Charlene Breedlove, Anne Rentoumis Cappola, MD, ScM, Helene M. Cole, MD, Thomas B. Cole, MD, MPH, W. Gregory Feero, MD, PhD, J. Michael Gaziano, MD, MPH, Donald C. Goff, MD, Preeti N. Malani, MD, MSJ, David H. Mark, MD, MPH, Robert A. McNutt, MD, George T. O’Connor, MD, MS, Boris Pasche, MD, PhD, Eric D. Peterson, MD, MPH, Jeffrey L. S...
The delivery systems of two long-acting formulations of methylphenidate (MPH) were designed for different durations. Diffucaps bead-delivery system (DBDS)-MPH was designed to last 8 h and osmotically controlled-release oral delivery system (OROS)-MPH was designed to last 12 h. While the plasma pharmacokinetics and timing of efficacy have been studied, the corresponding central nervous system do...
BACKGROUND Methylphenidate (MPH), a psychostimulant drug used to treat attention-deficit/hyperactivity disorder, produces the effects of increasing alertness and improving attention. However, misuse of MPH has been associated with an increased risk of aggression and psychosis. We sought to determine the molecular mechanism underlying the complex actions of MPH. METHODS Adolescent (4-week-old)...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید